Crossmark

Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial

Crossref DOI link: https://doi.org/10.1007/s00280-018-3650-4

Published Online: 2018-07-23

Published Print: 2018-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Wen

Du, Chunxia

Sun, Yongkun

Yang, Lin

Cui, Chengxu

Jiang, Zhichao

Wang, Chengfeng

Wang, Jinwang

Zhou, Aiping https://orcid.org/0000-0003-1632-837X
License Information

Text and Data Mining valid from 2018-07-23
More Information

Article History

Received: 18 June 2018

Accepted: 18 July 2018

First Online: 23 July 2018

Compliance with ethical standards

:

: Authors declare that they have no conflict of interest.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Ethical Committee of Cancer Institute and Hospital, Chinese Academy of Medical Sciences, no. 14–102/892.

: Informed consent was obtained from all individual participants included in the study.